Abstract:9618 Background: While studies suggest that variants in infammation genes explain individual variation in pain severity, these studies only assessed one or a few candidate genes. Given that pain is a complex trait, multiple genes with relatively small effects are likely to influence vulnerability to pain. In this study, we evaluated a comprehensive panel of 59 single nucleotide polymorphisms (SNP) in 37 inflammation genes in newly diagnosed non-Hispanic Caucasian lung cancer patients (n=667) and assessed their association with pain severity. We also assessed the extent to which clinical and demographic factors explain pain severity in this population. Methods: Patients rated their pain “during the past week” on an 11-point numeric scale, (0= ‘no pain’ and 10= ‘pain as bad as you can imagine’) at presentation, prior to initiating cancer therapy. A score > 7/10 was considered to indicate severe pain. Logistic regression analyses were conducted to assess the extent of association between genetic polymorphism and pain severity. All SNPs were genotyped using SNPlex. Results: Results showed that 16% of the sample reported severe pain. As expected, severe pain was more prevalent among those with advanced stage of disease (OR=2.34; 95% CI=1.50–3.65), younger age (OR=0.47; 95%CI=0.30–0.75), depressed mood (OR=3.68; 95%CI=1.96–6.93) and fatigue (OR=3.68; 95% CI=1.96–6.93). Of the 59 SNPs, we initially found SNPS in 6 genes [IKB 3’-UTR(C/T), TNFA -308GA, TNFB Arg13Cys, IL2-330T/G, IL8–251 T/A, COX2 3’-UTR(T/C)] to be significantly associated with severe pain. Controlling for clinical and demographic variables, we found that carriers of CC alleles for COX2 3’-UTR T/C (OR= 3.24; 95% CI=1.12, 9.39) and carriers of TT alleles for IL2-330T/G (OR=1.68; 95%CI=1.04, 2.73) persisted as significant correlates of severe pain. Conclusions: Because genetic polymorphisms are stable markers, understanding the extent to which genetic variability plays a role on cancer-related pain may prove useful in identifying patients at high-risk for pain development and importantly, could help in understanding patients who might benefit most from symptom intervention, and ultimately in developing personalized and more effective pain therapies. No significant financial relationships to disclose.

Molecular Genetics of Variability in Human Pain

Two Novel<i>SCN9A</i>Gene Heterozygous Mutations May Cause Partial Deletion of Pain Perception

Genetic architecture of human pain perception

Genetic variability of pain perception and treatment—clinical pharmacological implications

The genetic mediation of individual differences in sensitivity to pain and its inhibition

Genetics of pain, opioids, and opioid responsiveness

Bridging the genetic gulf: a deep dive into neurotransmission, pharmacogenomics, and genetic variations for optimal pain management

Genetic contributions to pain: a review of findings in humans

Genetic and epigenetic of pain perception

From mouse to humans: discovery of the CACNG2 pain susceptibility gene

Is the Experience of Thermal Pain Genetics Dependent?

A multi-ancestry genetic study of pain intensity in 598,339 veterans

Effects of functional polymorphisms of opioid receptor mu 1 and catechol‐O‐methyltransferase on the neural processing of pain

Research progress of pain related genes

Genomic and transcriptomic profiles influence on brain morphology and their interactions with pain sensitivity individual differences

Deciphering the genetic architecture of pain intensity

Analysis of genetically independent phenotypes identifies shared genetic factors associated with chronic musculoskeletal pain conditions

Genetic contributions to pain modulation in sickle cell: A focus on single nucleotide polymorphisms

Genetics meets function in sodium channel-related pain disorders

Inflammation Genes and Pain Severity in Lung Cancer Patients

COMT Gene Variants and Β-Endorphin Levels Contribute to Ethnic Differences in Experimental Pain Sensitivity